<p>預計 <strong>唐納德·特朗普</strong> 將簽署一項行政命令，將大麻重新分類為 較低的聯邦藥物 分類。</p>
<p>特朗普本週早些時候公開表示，該問題正在積極考慮中，並告訴記者重新分類正在 “非常認真” 地權衡。將大麻從《受控物質法》第一類轉移到第三類。</p>
<p>毒品執法局將第一類藥物定義為沒有被接受的醫療用途且具有高濫用潛力，而第三類物質被認為具有中等到低的身體和心理依賴風險。</p>
<p><strong>另請閲讀: 特朗普考慮大麻變更：‘很多人想看到它’</strong></p>
<h2>關注股票</h2>
<ul>
<li><strong>Canopy Growth Corporation</strong> (NASDAQ: CGC)</li>
<li><strong>Tilray Brands Inc</strong>. (NASDAQ: TLRY)</li>
<li><strong>Akanda Corp</strong> (NASDAQ: AKAN)</li>
<li><strong>Aurora Cannabis Inc</strong> (NASDAQ: ACB)</li>
<li><strong>Cronos Group Inc</strong> (NASDAQ: CRON)</li>
<li><strong>Flora Growth Corp</strong> (NASDAQ: FLGC)</li>
<li><strong>GrowGeneration Corp</strong> (NASDAQ: GRWG)</li>
<li><strong>IM Cannabis Corp</strong> (NASDAQ: IMCC)</li>
<li><strong>Organigram Global Inc</strong> (NASDAQ: OGI)</li>
<li><strong>SNDL Inc</strong> (NASDAQ: SNDL)</li>
<li><strong>urban-gro, Inc.</strong> (NASDAQ: UGRO)</li>
<li><strong>cbdMD, Inc.</strong> (NYSE: YCBD)</li>
</ul>
<h2>大麻：從競選話題到現在</h2>
<p>特朗普在橢圓形辦公室發言時 告訴 CNN，重新分類可能會解鎖目前因聯邦法律而受限的科學進展。他指出，許多研究人員因大麻的第一類地位而面臨障礙，並補充説，改變可能為更廣泛的醫學研究打開大門。</p>
<p>這一潛在的行政行動是在特朗普 2024 年總統競選期間的評論之後提出的。</p>
<p>“我們還必須實施智能監管，同時為成年人提供安全、經過測試的產品的獲取，” 特朗普在 2024 年 9 月在 TruthSocial 上 發佈 説。“作為總統，我們將繼續專注於研究，以解鎖大麻作為第三類藥物的醫療用途，並與國會合作通過常識法律，包括為州授權公司提供安全銀行服務，並支持各州通過大麻法律，例如佛羅里達州，這對他們的公民非常有效。”</p>
<p>預計該命令不會在聯邦層面合法化大麻。相反，重新分類可能主要影響税收、研究批准、成年人對受監管產品的獲取以及各州在追求自身合法化框架方面的靈活性。</p>
<p><strong>下一步閲讀：</strong></p>
<ul>
<li><strong>維韋克·拉馬斯瓦米支持的比特幣國庫股票在首席執行官購買下跌後反彈</strong></li>
</ul>
<p><em>圖片來源：Shutterstock</em></p>

TLRY

<p>特朗普總統預計將簽署一項行政命令，將大麻從第一類藥物重新分類為第三類藥物，這將放寬聯邦限制，但仍未實現合法化。這一舉措可能會促進科學研究，併為各州的合法化框架提供更多靈活性。值得關注的股票包括 Canopy Growth、Tilray 和 Aurora Cannabis。特朗普強調對州授權公司實施智能監管和安全銀行業務</p>

<p>President <strong>Donald Trump</strong> is expected to sign an executive order that would reschedule cannabis to a lower federal drug classification.</p>
<div class="lb-trans"><p>預計 <strong>唐納德·特朗普</strong> 將簽署一項行政命令，將大麻重新分類為 較低的聯邦藥物 分類。</p>
</div><p>Trump publicly indicated earlier this week that the issue was under active consideration, telling reporters that reclassification was being weighed &#34;very strongly.&#34; Moving marijuana from Schedule I to Schedule III under the Controlled Substances Act.</p>
<div class="lb-trans"><p>特朗普本週早些時候公開表示，該問題正在積極考慮中，並告訴記者重新分類正在 “非常認真” 地權衡。將大麻從《受控物質法》第一類轉移到第三類。</p>
</div><p>The Drug Enforcement Administration defines Schedule I drugs as having no accepted medical use and a high potential for abuse, while Schedule III substances are considered to have a moderate to low risk of physical and psychological dependence.</p>
<div class="lb-trans"><p>毒品執法局將第一類藥物定義為沒有被接受的醫療用途且具有高濫用潛力，而第三類物質被認為具有中等到低的身體和心理依賴風險。</p>
</div><p><strong>Also Read: Trump Weighs Marijuana Changes: ‘A Lot Of People Want To See It’</strong></p>
<div class="lb-trans"><p><strong>另請閲讀: 特朗普考慮大麻變更：‘很多人想看到它’</strong></p>
</div><h2>Stock To Watch</h2>
<div class="lb-trans"><h2>關注股票</h2>
</div><ul>
<li><strong>Canopy Growth Corporation</strong> (NASDAQ: CGC)</li>
<li><strong>Tilray Brands Inc</strong>. (NASDAQ: TLRY)</li>
<li><strong>Akanda Corp</strong> (NASDAQ: AKAN)</li>
<li><strong>Aurora Cannabis Inc</strong> (NASDAQ: ACB)</li>
<li><strong>Cronos Group Inc</strong> (NASDAQ: CRON)</li>
<li><strong>Flora Growth Corp</strong> (NASDAQ: FLGC)</li>
<li><strong>GrowGeneration Corp</strong> (NASDAQ: GRWG)</li>
<li><strong>IM Cannabis Corp</strong> (NASDAQ: IMCC)</li>
<li><strong>Organigram Global Inc</strong> (NASDAQ: OGI)</li>
<li><strong>SNDL Inc</strong> (NASDAQ: SNDL)</li>
<li><strong>urban-gro, Inc.</strong> (NASDAQ: UGRO)</li>
<li><strong>cbdMD, Inc.</strong> (NYSE: YCBD)</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Canopy Growth Corporation</strong> (NASDAQ: CGC)</li>
<li><strong>Tilray Brands Inc</strong>. (NASDAQ: TLRY)</li>
<li><strong>Akanda Corp</strong> (NASDAQ: AKAN)</li>
<li><strong>Aurora Cannabis Inc</strong> (NASDAQ: ACB)</li>
<li><strong>Cronos Group Inc</strong> (NASDAQ: CRON)</li>
<li><strong>Flora Growth Corp</strong> (NASDAQ: FLGC)</li>
<li><strong>GrowGeneration Corp</strong> (NASDAQ: GRWG)</li>
<li><strong>IM Cannabis Corp</strong> (NASDAQ: IMCC)</li>
<li><strong>Organigram Global Inc</strong> (NASDAQ: OGI)</li>
<li><strong>SNDL Inc</strong> (NASDAQ: SNDL)</li>
<li><strong>urban-gro, Inc.</strong> (NASDAQ: UGRO)</li>
<li><strong>cbdMD, Inc.</strong> (NYSE: YCBD)</li>
</ul>
</div><h2>Cannabis: From Campaign Talking Point To Now</h2>
<div class="lb-trans"><h2>大麻：從競選話題到現在</h2>
</div><p>Speaking from the Oval Office, Trump told CNN that the reclassification could unlock scientific progress that is currently limited under federal law. He noted that many researchers face barriers studying marijuana because of its Schedule I status, adding that a change could open the door to broader medical research.</p>
<div class="lb-trans"><p>特朗普在橢圓形辦公室發言時 告訴 CNN，重新分類可能會解鎖目前因聯邦法律而受限的科學進展。他指出，許多研究人員因大麻的第一類地位而面臨障礙，並補充説，改變可能為更廣泛的醫學研究打開大門。</p>
</div><p>The potential executive action follows Trump’s comments during the 2024 presidential campaign.</p>
<div class="lb-trans"><p>這一潛在的行政行動是在特朗普 2024 年總統競選期間的評論之後提出的。</p>
</div><p>“We must also implement smart regulations, while providing access for adults, to safe, tested product,” Trump posted on TruthSocial in September 2024. “As President, we will continue to focus on research to unlock the medical uses of marijuana to a Schedule 3 drug, and work with Congress to pass common sense laws, including safe banking for state authorized companies, and supporting states rights to pass marijuana laws, like in Florida, that work so well for their citizens.”</p>
<div class="lb-trans"><p>“我們還必須實施智能監管，同時為成年人提供安全、經過測試的產品的獲取，” 特朗普在 2024 年 9 月在 TruthSocial 上 發佈 説。“作為總統，我們將繼續專注於研究，以解鎖大麻作為第三類藥物的醫療用途，並與國會合作通過常識法律，包括為州授權公司提供安全銀行服務，並支持各州通過大麻法律，例如佛羅里達州，這對他們的公民非常有效。”</p>
</div><p>The anticipated order would not legalize marijuana at the federal level. Instead, rescheduling could primarily affect taxation, research approvals, adult access to regulated products, and state flexibility in pursuing their own legalization frameworks.</p>
<div class="lb-trans"><p>預計該命令不會在聯邦層面合法化大麻。相反，重新分類可能主要影響税收、研究批准、成年人對受監管產品的獲取以及各州在追求自身合法化框架方面的靈活性。</p>
</div><p><strong>Read Next:</strong></p>
<div class="lb-trans"><p><strong>下一步閲讀：</strong></p>
</div><ul>
<li><strong>Vivek Ramaswamy-Backed Bitcoin Treasury Stock Rallies After CEO Buys Dip Following 25% Pullback</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>維韋克·拉馬斯瓦米支持的比特幣國庫股票在首席執行官購買下跌後反彈</strong></li>
</ul>
</div><p><em>Image: Shutterstock</em></p>
<div class="lb-trans"><p><em>圖片來源：Shutterstock</em></p>
</div>

白宮考慮對大麻進行重新分類，但尚未實現合法化：值得關注的股票